Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy.

Authors: Chuthapisith, S  Bean, BE  Cowley, G  Eremin, JM  Samphao, S  Layfield, R  Kerr, ID  Wiseman, J  El-Sheemy, M  Sreenivasan, T  Eremin, O 
Citation: Chuthapisith S, etal., Eur J Cancer. 2009 May;45(7):1274-81. doi: 10.1016/j.ejca.2008.12.026. Epub 2009 Jan 24.
Pubmed: (View Article at PubMed) PMID:19171478
DOI: Full-text: DOI:10.1016/j.ejca.2008.12.026

Neoadjuvant chemotherapy is used in women who have large or locally advanced breast cancers. However, up to 70% of women who receive neoadjuvant chemotherapy fail to achieve a complete pathological response in their primary tumour (a surrogate marker of long-term survival). Five proteins, previously identified to be linked with chemoresistance in our in vitro experiments, were identified histochemically in pre-treatment core needle biopsies from 40 women with large or locally advanced breast cancers. Immunohistochemical staining with the five proteins showed no single protein to be a predictor of response to chemotherapy. However, pre-treatment breast cancer specimens that were annexin-A2 positive but annexin-A1 negative correlated with a poor pathological response (p=0.04, Fisher's exact test). The mechanisms by which annexins confer chemoresistance have not been identified, but may be due to inhibition of apoptosis. Annexin-A1 has been shown to enhance apoptosis, whilst annexin-A2, by contrast, inhibits apoptosis.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 7421560
Created: 2013-11-21
Species: All species
Last Modified: 2013-11-21
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.